Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

European Post-Authorization Safety Study (PASS) Study of SCENESSE in Adult Erythropoietic Protoporphyria Patients

Next Previous
Search
Trial Profile

European Post-Authorization Safety Study (PASS) Study of SCENESSE in Adult Erythropoietic Protoporphyria Patients

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afamelanotide (Primary)
  • Indications Erythropoietic protoporphyria
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 10 Sep 2019 According to a Clinuvel Pharmaceuticals media release, long-term safety and effectiveness data from the treatment of erythropoietic protoporphyria (EPP) patients with SCENESSE (afamelanotide 16mg), from this study will be presented this week at the International Congress on Porphyrins and Porphyrias (ICPP) in Milan, Italy.
    • 29 Mar 2019 According to a Clinuvel Pharmaceuticals media release, Clinicians and medical staff from a number of EPP expert centres will participate in the full day meetings focused on results from this ongoing study.
    • 05 Apr 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top